Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02994251
Other study ID # 1603017367
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 21, 2017
Est. completion date November 6, 2018

Study information

Verified date December 2019
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient follow-up.


Description:

Eligible patients enrolled on study will receive a chemotherapy regimen of gemcitabine and cisplatin administered intravenously on Days 1 and 8 of a 21-day cycle. After every 2 cycles of systemic chemotherapy, patients will receive contrast-enhanced MRI to assess liver disease; conventional trans-arterial chemoembolization (TACE) will be performed as indicated based on this assessment. Patients will receive a maximum of 8 cycles of the gemcitabine/cisplatin combination. Up to 3 TACE treatments may be delivered in this same time frame, with the first TACE taking place after 2 cycles of systemic chemotherapy. Following the treatment period, patients will continue clinical follow-up at 3 month intervals until study exit at 18 months post the start of treatment.

It is hypothesized that the addition of conventional transarterial chemoembolization to standard chemotherapy will result in an improvement in PFS in patients with advanced, unresectable ICC, including patients with extra-hepatic disease.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date November 6, 2018
Est. primary completion date November 6, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient is at least 18 years of age.

- Patient has advanced, unresectable intrahepatic cholangiocarcinoma (ICC). Advanced, unresectable ICC is defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.

- Eligible for conventional TACE as defined by local treatment guidelines.

- Child-Pugh class of A to B7.

- Adequate end-organ and bone marrow function as manifested as:

- Hemoglobin = 9 g/dL

- Absolute neutrophil count = 1500/mm3

- Creatinine = 2.0 g/dL

- AST and ALT = 5 x ULN

- Albumin = 2.4 mg/dL

- Total bilirubin = 2.5 mg/dL

- Platelets = 100,000/mm3

- For TACE procedures, subjects are allowed to have platelets = 75,000/mm3.

- Disease is liver-dominant with >70% of measurable disease burden within the hepatic parenchyma.

- No prior surgery or chemotherapy for ICC.

- ECOG performance status of 0-1.

- No other active malignancy within 2 years.

- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study.

- Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

- Prior or concurrent chemotherapy treatment for advanced ICC.

- History of allergic reactions attributed to compounds of similar chemical or biological composition to gemcitabine, cisplatin, doxorubicin, or mitomycin-C.

- Active treatment with CYP3A4 strong inhibitors or inducers.

- Recent surgical procedure within 21 days of study enrollment.

- Severe and/or uncontrolled co-morbid medical conditions including, but not limited to, active infection, viral hepatitis, congestive heart failure, cardiac arrhythmia, unstable angina pectoris, and psychiatric illness or social circumstance that would limit compliance with study requirements.

- Pregnancy during study duration.

- Active immunosuppressive medications.

- Presence of grade 2 or higher hepatic encephalopathy.

- Complete occlusion of the entire portal venous system. Partial or branch portal vein occlusion allowed if without reversal of flow.

- Radiotherapy within 21 days from treatment with study interventions or medications.

- Current, recent (within 4 weeks of first infusion of this study), or planned participation in additional experimental drug.

- Unstable angina.

- New York Heart Association (NYHA) Grade II or greater congestive heart failure (Appendix C).

- History of myocardial infarction or CVA within 6 months prior to study enrollment.

- Clinically significant peripheral vascular disease.

- Inability to comply with study and/or follow-up procedures.

- Life expectancy of less than 12 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
gemcitabine
1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
Cisplatin
25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.

Locations

Country Name City State
United States Smilow Cancer Center New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival The primary objective of this study is to evaluate the 12-month progression-free survival (PFS) rate in adult patients with intrahepatic cholangiocarcinoma (ICC) after treatment with gemcitabine and cisplatin in combination with conventional TACE. This is the percentage of patients alive and free of progression at 12-months from enrollment on study. Radiographic assessment of disease burden will be evaluated by mRECIST and qEASL using an MRI scan obtained at the IR clinic visit. 12 months
Secondary Overall Survival Evaluation of overall survival (OS) of adult patients with advanced ICC treated with gemcitabine and cisplatin in combination with conventional TACE. Overall survival is the time from enrollment on study until death of the patient from any cause. 18 months
Secondary Overall Time to Progression (TTP) Overall TTP is the time from enrollment on study until radiographic evidence of overall disease progression. Radiographic assessment will be evaluated by mRECIST using MRI every 2 cycles after intra-arterial therapy. up to 18 months
Secondary Time to Untreatable Progression (TTUP) TTUP in liver lesions is measured from the time of initiation on cTACE therapy until radiographic evidence of disease progression in targeted lesions. Radiographic assessment will be evaluated by mRECIST using MRI every 2 cycles after intra-arterial therapy. up to 18 months
Secondary Toxicities of the Gemcitabine and Cisplatin Regimen in Combination With cTACE Therapy Using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. To evaluate the toxicities of the gemcitabine and cisplatin regimen in combination with cTACE therapy in adult patients with advanced ICC. Safety will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 18 months
Secondary Correlation Between Changes in Dynamic Contrast-enhanced MRI of Liver Lesions and Progression Free Survival early changes in dynamic contrast-enhanced MRI (DCE-MRI) will correlate with long term PFS or OS, specifically as they relate to lesions targeted with cTACE therapy 18 months
Secondary Correlation Between Changes in Dynamic Contrast-enhanced MRI of Liver Lesions and Overall Survival early changes in dynamic contrast-enhanced MRI (DCE-MRI) will correlate with long term OS, specifically as they relate to lesions targeted with cTACE therapy 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT03942328 - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Phase 1/Phase 2
Terminated NCT02256982 - A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma N/A
Active, not recruiting NCT04175912 - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Phase 2
Recruiting NCT06058663 - Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Phase 1
Recruiting NCT05738057 - Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT01648023 - Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin Phase 2
Recruiting NCT05564403 - Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Phase 2
Active, not recruiting NCT03768414 - Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Phase 3
Completed NCT04301778 - Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Phase 2
Active, not recruiting NCT04251715 - mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma Phase 2